These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17065348)

  • 1. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.
    Mastorikou M; Mackness M; Mackness B
    Diabetes; 2006 Nov; 55(11):3099-103. PubMed ID: 17065348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
    Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
    Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
    Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
    Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
    Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
    Girona J; Manzanares JM; Marimón F; Cabré A; Heras M; Guardiola M; Ribalta J; Masana L
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
    Jornayvaz FR; Brulhart-Meynet MC; James RW
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):613-9. PubMed ID: 19201174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
    Li C; Gu Q
    Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
    Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
    Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes.
    Inoue M; Suehiro T; Nakamura T; Ikeda Y; Kumon Y; Hashimoto K
    Metabolism; 2000 Nov; 49(11):1400-5. PubMed ID: 11092501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.
    Mastorikou M; Mackness B; Liu Y; Mackness M
    Diabet Med; 2008 Sep; 25(9):1049-55. PubMed ID: 18937674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.
    Tsuzura S; Ikeda Y; Suehiro T; Ota K; Osaki F; Arii K; Kumon Y; Hashimoto K
    Metabolism; 2004 Mar; 53(3):297-302. PubMed ID: 15015140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
    Deakin SP; James RW
    Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.
    Mackness B; Quarck R; Verreth W; Mackness M; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1545-50. PubMed ID: 16627808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy.
    Pérez-Herrera N; May-Pech C; Hernández-Ochoa I; Castro-Mañé J; Rojas-García E; Borja-Aburto VH; Castillo-Burguete T; Quintanilla-Vega B
    Exp Mol Pathol; 2008 Oct; 85(2):129-34. PubMed ID: 18582459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.
    Sampson MJ; Braschi S; Willis G; Astley SB
    Clin Sci (Lond); 2005 Aug; 109(2):189-97. PubMed ID: 15853770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
    Quéméneur T; Martin-Nizard F; Kandoussi A; Kyndt X; Vanhille P; Hachulla E; Hatron PY; Fruchart JC; Duriez P; Lambert M
    Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.